Invizius Secures £950k Funding to Advance H-Guard Treatment
In the fast-paced world of biotech, breakthroughs often hinge on visionary ideas and dedicated funding. Recently, Invizius, an innovative company based in Edinburgh, is making waves in the healthcare landscape with a groundbreaking treatment for patients undergoing dialysis. With an impressive £950k in funding, this startup is poised to advance its pioneering H-Guard product—a game changer for individuals battling acute kidney injury in intensive care units (ICUs).
Founded in 2018 as a spin-out from the prestigious University of Edinburgh, Invizius is led by the ambitious CEO, Magnus Nicolson.
The latest funding round was spearheaded by Mercia Ventures, with essential support from notable investors including Calculus Capital, Syensqo, Old College Capital from the University of Edinburgh, and Scottish Enterprise. This infusion of capital will facilitate crucial preparations for the next stages of clinical trials focused on H-Guard, a treatment that seeks to combat the dangerous inflammatory responses frequently triggered during dialysis procedures.
The potential of H-Guard is profound; it aims to not only modify the immune response but also to mitigate renal tubule damage—two critical factors in improving patient outcomes during dialysis. Following a successful 'First in Human' study earlier this year, which highlighted the product's safety and produced promising biomarker data, Invizius is on the brink of transforming patient care in critical settings. With this recent funding, the total amount raised by the company has soared to over £13 million, further solidifying its position as an enticing venture for investors looking to make a significant impact in the healthcare sector.
Key Terms Explained
- Funding
- Monetary resources provided to startups and businesses to help them initiate, continue or complete projects. In this context, funding refers to the £950k provided to Invizius to develop their H-Guard product.
- Clinical Trials
- Studies conducted to test whether a medical strategy, treatment, or device is safe and effective for humans. In the extract, clinical trials are noted to be the next step for the H-Guard treatment.
- Investors
- Individuals or institutions that provide capital to start or expand a business in exchange for financial returns or equity. In this text, investors like Mercia Ventures, Calculus Capital, Syensqo, Old College Capital, and Scottish Enterprise have contributed to Invizius' recent funding round.
Frequently Asked Questions
- What is the startup that recently received impressive funding for its healthcare breakthrough?-The startup that recently received impressive funding for its healthcare breakthrough is Invizius.
- What is the special product that Invizius is developing with its funding?+
- Who were the primary investors in the latest funding round for Invizius?+
- What is the potential impact of Invizius' product, H-Guard?+
- What is the total funding amount raised by Invizius to date?+
They've invested in Invizius
Get to know these Healthtech investors
Click here for a full list of 6,908+ startup investors in the UK